Screener / SEC EDGAR /CIK 0001699031 /10-K filed Mar 12, 2026, compared with Mar 5, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Medical Labs

GRAIL, Inc. GRAL

Compare with peers Embed
Earnings releases

Latest results release: Nov 4, 2026

8-K item 2.02, exhibit 99

What GRAL's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Adjusted vs GAAP earnings per share

In the company's own words · read from each release, never computed

What the company says its adjusted numbers leave out:

• We calculate Adjusted EBITDA as net income (loss) adjusted to exclude interest (income) expense, income tax expense (benefit), depreciation, impairment of goodwill and intangible assets, and amortization of intangible assets, which represent intangible assets resulting from pushdown accounting, legal and professional services fees related to Illumina’s acquisition of the Company in August 2021 (“the Acquisition”) and corresponding antitrust litigation, including compliance with the hold separate arrangements imposed by the European Commission, and our divestment from Illumina, restructuring charges, and stock- based compensation. release Aug 12, 2025

Both numbers are read from the words of each release (usually the highlights), never computed by us; hover a number for its sentence. Quarters where the release gives them only in a table are not shown. The company decides what "adjusted" leaves out; the full reconciliation is in the release.

Read and search

Every release, in full · linked to sec.gov

Press release Nov 4, 2026 · EX-99.1

GRAIL Reports Third Quarter 2026 Financial Results

Open on SEC

FDA Advisory Committee Voted in Favor of Approval of GRAIL’s Galleri Multi- Cancer Early Detection Test

Test Volume Increased ~24% to More Than 56,000 Year-Over-Year, Year-to-Date Test Volume Increased ~36% to More Than 174,000

Q3 Galleri Revenue Grew 14% Year-Over-Year to $37.3 Million SUNNYVALE, Calif. — Nov. 4, 2026 — GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the third quarter of 2026.

Galleri test revenue for the third quarter grew 14% year-over-year to $37.3 million, and total revenue grew 4% year-over-year to $37.5 million. Galleri test volume for the third quarter grew approximately 24% year-over-year to more than 56,000 tests. Total Galleri test volume and revenue for the nine months ended September 30, 2026 grew 36% year-over-year to more than 174,000 tests and 24% to $119.7 million, respectively. Net loss for the third quarter was $103.6 million. Gross loss was $18.1 million. Non-GAAP adjusted gross profit was $15.9 million, and non-GAAP adjusted EBITDA was $(92.6) million. 1

“GRAIL achieved significant milestones this quarter including a favorable vote for approval of Galleri at the FDA Advisory Committee,” said Josh Ofman, MD, MSHS, Chief Executive Officer of GRAIL. “This achievement strengthens the foundation for Galleri as we continue on our path towards potential regulatory approval, broader access and reimbursement. We are seeing continued commercial momentum as a number of positive advancements, consistent market education, and promotional pricing initiatives gain traction.”

For the three months ended September 30, 2026, as compared to the three months ended September 30, 2025, GRAIL reported:

• Revenue: Total revenue, comprised of screening and development services revenue, was $37.5 million, an increase of $1.3 million or 4%.

: Adjusted EBITDA was $(92.6) million, an increase in adjusted EBITDA loss of $20.9 million or 29%.

• Cash position: Cash, cash equivalents, and short-term marketable securities totaled $788.7 million as of September 30, 2026.

1 See “Non-GAAP Disclosure” and the associated reconciliations for important information about our use of non-GAAP measures.

• Announced a favorable vote for approval of the Galleri test from the FDA's Molecular and Clinical Genetics Panel of the Medical Device Advisory Committee (the “Advisory Committee”) in September. The company anticipates an FDA decision by early Q1 2027.

• Published results from the NHS-Galleri trial in The New England Journal of Medicine and Nature Medicine, and final results from the PATHFINDER 2 study in Nature Medicine. The publications report clinical utility, test performance, and safety results from approximately 175,000 participants enrolled in the UK and North America. The results across the studies demonstrated:

◦ Substantially increased cancer detection (4-6.5x more cancers detected) with robust performance, a favorable safety profile and consistent clinical performance across the two large trials.

◦ Additionally, the NHS-Galleri trial demonstrated a substantial reduction of >20% in Stage IV diagnoses of 12 prespecified aggressive cancers and a 25% reduction in cancers diagnosed after emergency presentation in the Galleri arm compared to the control arm.

◦ In the NHS-Galleri trial, Galleri added to standard-of-care screening detected more Stage I-II cancers than the UK national screening program found all cancers across all stages.

These data support the potential of multi-cancer early detection screening at population scale to identify cancers before symptoms appear — when they can be treated more easily and are potentially curable.

A webcast and conference call will be held today, Nov. 4, 2026, at 1:30 p.m. PT / 4:30 p.m. ET. Individuals interested in listening to the conference call may access it on the investor relations section of GRAIL’s website at investors.grail.com.

GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL’s targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Sunnyvale, Calif. with locations in Washington, D.C., North Carolina, and the United Kingdom. GRAIL’s common stock is listed under the ticker symbol “GRAL” on the Nasdaq Stock Exchange.

The Galleri multi-cancer early detection test is a proactive tool to screen for cancer. With a simple blood draw, the Galleri test can identify DNA shed by cancer cells, which can act as a unique “fingerprint” of cancer, to help screen for some of the deadliest cancers that don’t have recommended screening today, such as pancreatic, esophageal, ovarian, liver, and others. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer, giving healthcare providers a roadmap of where to explore further. The Galleri test requires a prescription from a licensed healthcare provider and should be used in addition to recommended cancer screenings such as mammography, colonoscopy, prostate-specific antigen (PSA) test, or cervical cancer screening. The Galleri test is recommended for adults with an elevated risk for cancer, such as those aged 50 or older.

The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed — and its performance characteristics were determined — by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. The GRAIL clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.

In addition to our financial results provided throughout this press release that are determined in accordance with U.S. generally accepted accounting principles (“GAAP”), this press release also includes financial measures that are not calculated in accordance with GAAP. Our non-GAAP financial disclosure includes Adjusted Gross Profit, Adjusted Gross Margin and Adjusted EBITDA. We encourage investors to carefully consider our results under GAAP in conjunction with our supplemental non-GAAP information and the reconciliation between these presentations.

• Adjusted Gross Profit and Adjusted Gross Margin are key performance measures that our management uses to assess our operational performance, as they represent the results of revenues and direct costs, which are key components of our operations. We believe that these non-GAAP financial measures are useful to investors and other interested parties in analyzing our financial performance because they reflect the gross profitability of our operations, and exclude the costs associated with our sales and marketing, product development, general and administrative activities and the impact of our financing methods and income taxes.

We calculate Adjusted Gross Profit as gross profit (loss) (as defined below) adjusted to exclude amortization of intangible assets and stock-based compensation allocated to cost of revenue. Adjusted Gross Profit should be viewed as a measure of operating performance that is a supplement to, and not a substitute for, operating income or loss from operations, net earnings or loss and other GAAP measures of income (loss) or profitability. Gross profit (loss) (as defined below) is the most directly comparable financial measure calculated in accordance with GAAP. We calculate Adjusted Gross Margin as Adjusted Gross Profit divided by total revenue. 3 • Adjusted EBITDA is a key performance measure that our management uses to assess our financial performance and is also used for internal planning and forecasting purposes. We believe that this non-GAAP financial measure is useful to investors and other interested parties in analyzing our financial performance because it provides a comparable overview of our operations across historical periods. In addition, we believe that providing Adjusted EBITDA, together with a reconciliation of net loss to Adjusted EBITDA, helps investors make comparisons between our company and other companies that may have different capital structures, different tax rates, different operational and ownership histories, and/or different forms of employee compensation.

Adjusted EBITDA is used by our management team as an additional measure of our performance for purposes of business decision-making, including managing expenditures. Period-to-period comparisons of Adjusted EBITDA help our management identify additional trends in our financial results that may not be shown solely by period-to-period comparisons of net income (loss) or income (loss) from operations. Our management recognizes that Adjusted EBITDA has inherent limitations because of the excluded items, and may not be directly comparable to similarly titled metrics used by other companies.

The Company defines Adjusted EBITDA as net loss adjusted for amortization of intangible assets, stock-based compensation, depreciation, intangible and other assets impairment, benefit from income taxes, interest income and restructuring expenses. These adjustments include non-cash items, significant non-recurring charges and/or other non-operating expenses that we do not believe are indicative of ongoing or future business operations.

Adjusted EBITDA should be viewed as a measure of operating performance that is a supplement to, and not a substitute for, operating income or loss from operations, net earnings or loss and other U.S. GAAP measures of income (loss). Additionally, it is not intended to be a measure of free cash flow for management’s discretionary use, as it does not consider certain cash requirements such as interest and tax payments. Further, our definition of Adjusted EBITDA may differ from similarly titled measures used by other companies and therefore may not be comparable among companies. Net loss is the most directly comparable financial measure calculated in accordance with GAAP.

Full reconciliation of these non-GAAP measures to the most comparable GAAP measures is set forth in tabular form following the Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Operations.

This press release contains forward-looking statements. In some cases, you can identify these statements by forward-looking words such as “aim,” “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “should,” “would,” or “will,” the negative of these terms, and other comparable terminology. These forward-looking statements, which are subject to risks, uncertainties, and assumptions about us, may include statements related to the potential benefits, uses and impacts of the Galleri test, comparability of clinical study results to a real world setting, benefits of population screening with existing or future versions of Galleri, commercial and expansion plans, growth trends and reimbursement, potential regulatory decision timeline and outcome, and impacts of our commercial strategies, among others. 4 These statements are only predictions based on our current expectations and projections about future events and trends. There are important factors that could cause our actual results, level of activity, performance, or achievements to differ materially and adversely from those expressed or implied by the forward-looking statements, including those factors and numerous associated risks discussed under the sections entitled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025 and our subsequent Quarterly Reports on Form 10-Q. Moreover, we operate in a dynamic and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results, level of activity, performance, or achievements to differ materially and adversely from those contained in any forward-looking statements we may make.

Forward-looking statements relate to the future and, accordingly, are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Although we believe the expectations and projections expressed or implied by the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. Our actual results, financial condition and success in our business strategies and operations may differ materially from those indicated in the forward-looking statements. Except to the extent required by law, we undertake no obligation to update any of these forward-looking statements after the date of this press release to conform our prior statements to actual results or revised expectations or to reflect new information or the occurrence of unanticipated events.

September 30, December 31, 2026 2025 ────────────────────────────────────────────────────────────────────────────── Assets Current assets: Cash and cash equivalents $ 28,976 $ 249,727 Short-term marketable securities 759,700 654,703 Accounts receivable, net 18,998 18,295 Supplies 18,475 16,017 Prepaid expenses and other current 16,649 15,107 assets Total current assets 842,798 953,849 Property and equipment, net 42,691 51,813 Operating lease right-of-use assets 84,073 52,070 Restricted cash 6,943 6,974 Intangible assets, net 1,746,806 1,850,556 Other non-current assets 7,251 6,753 Total assets $ 2,730,562 $ 2,922,015 Liabilities and stockholders’ equity Current liabilities: Accounts payable $ 10,209 $ 2,083 Accrued liabilities 76,305 63,945 Operating lease liabilities, current 6,272 11,715 portion Other current liabilities 1,546 1,927 Total current liabilities 94,332 79,670 Operating lease liabilities, net of 79,576 43,148 current portion Deferred tax liability, net 99,742 218,583 Other non-current liabilities 3,393 2,752 Total liabilities 277,043 344,153 Preferred stock, par value of $0.001 per share; 50,000,000 shares authorized, no — — shares issued and outstanding as of September 30, 2026 and December 31, 2025 Common stock $0.001 par value per share, 1,500,000,000 shares authorized as of September 30, 2026 and December 31, 2025 45 40 and 44,753,179 and 40,331,360 shares issued and outstanding as of September 30, 2026 and December 31, 2025 Additional paid-in capital 12,970,363 12,786,848 Accumulated other comprehensive 1,794 2,655 income Accumulated deficit -10,518,683 -10,211,681 Total stockholders' equity 2,453,519 2,577,862 Total liabilities and stockholders' $ 2,730,562 $ 2,922,015 equity

(1) Gross loss is calculated as total revenue less cost of screening revenue (exclusive of amortization of intangible assets), cost of development services revenue and cost of revenue—amortization of intangible assets.

(2) Adjusted Gross Margin is calculated as adjusted gross profit divided by total revenue. 8

(1) Represents amortization of intangible assets, including developed technology and trade names.

(2) Represents the impairment charge related to the deferred asset recognized in connection with the Samsung SPA in the second quarter of 2026 and the in-process research and development ("IPR&D") impairment charge in the prior period. 9

Full text with the tables
                                                                                
   NEWS RELEASE                                                                 
                                                                                
                                                                                
  Exhibit 99.1                                                                  
                                                                                
                                                                                
               GRAIL Reports Third Quarter 2026 Financial Results               
                                                                                
  FDA Advisory Committee Voted in Favor of Approval of GRAIL’s Galleri Multi-   
                          Cancer Early Detection Test                           
                                                                                
                                   Q3 Galleri                                   
                                                                                
                                                                                
                                       ®                                        
                                                                                
Test Volume Increased ~24% to More Than 56,000 Year-Over-Year, Year-to-Date Test
                   Volume Increased ~36% to More Than 174,000                   
                                                                                
          Q3 Galleri Revenue Grew 14% Year-Over-Year to $37.3 Million           
SUNNYVALE, Calif. — Nov. 4, 2026 — GRAIL, Inc. (Nasdaq: GRAL), a healthcare
company whose mission is to detect cancer early when it can be cured, today
reported business and financial results for the third quarter of 2026.

Galleri test revenue for the third quarter grew 14% year-over-year to $37.3
million, and total revenue grew 4% year-over-year to $37.5 million. Galleri test
volume for the third quarter grew approximately 24% year-over-year to more than
56,000 tests. Total Galleri test volume and revenue for the nine months ended
September 30, 2026 grew 36% year-over-year to more than 174,000 tests and 24% to
$119.7 million, respectively. Net loss for the third quarter was $103.6 million.
Gross loss was $18.1 million. Non-GAAP adjusted gross profit was $15.9 million,
and non-GAAP adjusted EBITDA was $(92.6) million. 1

“GRAIL achieved significant milestones this quarter including a favorable vote
for approval of Galleri at the FDA Advisory Committee,” said Josh Ofman, MD,
MSHS, Chief Executive Officer of GRAIL. “This achievement strengthens the
foundation for Galleri as we continue on our path towards potential regulatory
approval, broader access and reimbursement. We are seeing continued commercial
momentum as a number of positive advancements, consistent market education, and
promotional pricing initiatives gain traction.”

For the three months ended September 30, 2026, as compared to the three months
ended September 30, 2025, GRAIL reported:

• Revenue: Total revenue, comprised of screening and development services
revenue, was $37.5 million, an increase of $1.3 million or 4%.

• Net loss: Net loss was $103.6 million, an increase of $14.6 million or 16%.

• Gross loss: Gross loss was $18.1 million, an increase of $4.4 million or 32%.

•
                                                                                
  Adjusted gross profit                                                         
                                                                                
                                                                                
  1                                                                             
                                                                                
: Adjusted gross profit was $15.9 million, a decrease of $4.1 million or 20%.

•
                                                                                
  Adjusted EBITDA                                                               
                                                                                
                                                                                
  1                                                                             
                                                                                
: Adjusted EBITDA was $(92.6) million, an increase in adjusted EBITDA loss of
$20.9 million or 29%.

• Cash position: Cash, cash equivalents, and short-term marketable securities
totaled $788.7 million as of September 30, 2026.

1 See “Non-GAAP Disclosure” and the associated reconciliations for important
information about our use of non-GAAP measures.

Recent business highlights include:

• Announced a favorable vote for approval of the Galleri test from the FDA's
Molecular and Clinical Genetics Panel of the Medical Device Advisory Committee
(the “Advisory Committee”) in September. The company anticipates an FDA decision
by early Q1 2027.

• Published results from the NHS-Galleri trial in The New England Journal of
Medicine and Nature Medicine, and final results from the PATHFINDER 2 study in
Nature Medicine. The publications report clinical utility, test performance, and
safety results from approximately 175,000 participants enrolled in the UK and
North America. The results across the studies demonstrated:

◦ Substantially increased cancer detection (4-6.5x more cancers detected) with
robust performance, a favorable safety profile and consistent clinical
performance across the two large trials.

◦ Additionally, the NHS-Galleri trial demonstrated a substantial reduction of
>20% in Stage IV diagnoses of 12 prespecified aggressive cancers and a 25%
reduction in cancers diagnosed after emergency presentation in the Galleri arm
compared to the control arm.

◦ In the NHS-Galleri trial, Galleri added to standard-of-care screening detected
more Stage I-II cancers than the UK national screening program found all cancers
across all stages.

These data support the potential of multi-cancer early detection screening at
population scale to identify cancers before symptoms appear — when they can be
treated more easily and are potentially curable.
                                                                                
  Conference Call and Webcast                                                   
                                                                                
A webcast and conference call will be held today, Nov. 4, 2026, at 1:30 p.m. PT
/ 4:30 p.m. ET. Individuals interested in listening to the conference call may
access it on the investor relations section of GRAIL’s website at
investors.grail.com.

A replay of the webcast will be available on GRAIL’s website for 30 days.
                                                                                
  About GRAIL                                                                   
                                                                                
GRAIL is a healthcare company whose mission is to detect cancer early, when it
can be cured. GRAIL is focused on alleviating the global burden of cancer by
using the power of next-generation sequencing, population-scale clinical
studies, and state-of-the-art machine learning, software, and automation to
detect and identify multiple deadly cancer types in earlier stages. GRAIL’s
targeted methylation-based platform can support the continuum of care for
screening and precision oncology, including multi-cancer early detection in
symptomatic patients, risk stratification, minimal residual disease detection,
biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered
in Sunnyvale, Calif. with locations in Washington, D.C., North Carolina, and the
United Kingdom. GRAIL’s common stock is listed under the ticker symbol “GRAL” on
the Nasdaq Stock Exchange.

For more information, visit grail.com .
                                       2                                        
                                                                                
  About Galleri®                                                                
                                                                                
The Galleri multi-cancer early detection test is a proactive tool to screen for
cancer. With a simple blood draw, the Galleri test can identify DNA shed by
cancer cells, which can act as a unique “fingerprint” of cancer, to help screen
for some of the deadliest cancers that don’t have recommended screening today,
such as pancreatic, esophageal, ovarian, liver, and others. The Galleri test can
be used to screen for cancer before a person becomes symptomatic, when cancer
may be more easily treated and potentially curable. The Galleri test can
indicate the origin of the cancer, giving healthcare providers a roadmap of
where to explore further. The Galleri test requires a prescription from a
licensed healthcare provider and should be used in addition to recommended
cancer screenings such as mammography, colonoscopy, prostate-specific antigen
(PSA) test, or cervical cancer screening. The Galleri test is recommended for
adults with an elevated risk for cancer, such as those aged 50 or older.

For more information, visit galleri.com .
                                                                                
  Laboratory/Test Information                                                   
                                                                                
The GRAIL clinical laboratory is certified under the Clinical Laboratory
Improvement Amendments of 1988 (CLIA) and accredited by the College of American
Pathologists. The Galleri test was developed — and its performance
characteristics were determined — by GRAIL. The Galleri test has not been
cleared or approved by the Food and Drug Administration. The GRAIL clinical
laboratory is regulated under CLIA to perform high-complexity testing. The
Galleri test is intended for clinical purposes.
                                                                                
  Non-GAAP Disclosure                                                           
                                                                                
In addition to our financial results provided throughout this press release that
are determined in accordance with U.S. generally accepted accounting principles
(“GAAP”), this press release also includes financial measures that are not
calculated in accordance with GAAP. Our non-GAAP financial disclosure includes
Adjusted Gross Profit, Adjusted Gross Margin and Adjusted EBITDA. We encourage
investors to carefully consider our results under GAAP in conjunction with our
supplemental non-GAAP information and the reconciliation between these
presentations.

• Adjusted Gross Profit and Adjusted Gross Margin are key performance measures
that our management uses to assess our operational performance, as they
represent the results of revenues and direct costs, which are key components of
our operations. We believe that these non-GAAP financial measures are useful to
investors and other interested parties in analyzing our financial performance
because they reflect the gross profitability of our operations, and exclude the
costs associated with our sales and marketing, product development, general and
administrative activities and the impact of our financing methods and income
taxes.

We calculate Adjusted Gross Profit as gross profit (loss) (as defined below)
adjusted to exclude amortization of intangible assets and stock-based
compensation allocated to cost of revenue. Adjusted Gross Profit should be
viewed as a measure of operating performance that is a supplement to, and not a
substitute for, operating income or loss from operations, net earnings or loss
and other GAAP measures of income (loss) or profitability. Gross profit (loss)
(as defined below) is the most directly comparable financial measure calculated
in accordance with GAAP. We calculate Adjusted Gross Margin as Adjusted Gross
Profit divided by total revenue.
                                       3                                        
• Adjusted EBITDA is a key performance measure that our management uses to
assess our financial performance and is also used for internal planning and
forecasting purposes. We believe that this non-GAAP financial measure is useful
to investors and other interested parties in analyzing our financial performance
because it provides a comparable overview of our operations across historical
periods. In addition, we believe that providing Adjusted EBITDA, together with a
reconciliation of net loss to Adjusted EBITDA, helps investors make comparisons
between our company and other companies that may have different capital
structures, different tax rates, different operational and ownership histories,
and/or different forms of employee compensation.

Adjusted EBITDA is used by our management team as an additional measure of our
performance for purposes of business decision-making, including managing
expenditures. Period-to-period comparisons of Adjusted EBITDA help our
management identify additional trends in our financial results that may not be
shown solely by period-to-period comparisons of net income (loss) or income
(loss) from operations. Our management recognizes that Adjusted EBITDA has
inherent limitations because of the excluded items, and may not be directly
comparable to similarly titled metrics used by other companies.

The Company defines Adjusted EBITDA as net loss adjusted for amortization of
intangible assets, stock-based compensation, depreciation, intangible and other
assets impairment, benefit from income taxes, interest income and restructuring
expenses. These adjustments include non-cash items, significant non-recurring
charges and/or other non-operating expenses that we do not believe are
indicative of ongoing or future business operations.

Adjusted EBITDA should be viewed as a measure of operating performance that is a
supplement to, and not a substitute for, operating income or loss from
operations, net earnings or loss and other U.S. GAAP measures of income (loss).
Additionally, it is not intended to be a measure of free cash flow for
management’s discretionary use, as it does not consider certain cash
requirements such as interest and tax payments. Further, our definition of
Adjusted EBITDA may differ from similarly titled measures used by other
companies and therefore may not be comparable among companies. Net loss is the
most directly comparable financial measure calculated in accordance with GAAP.

Full reconciliation of these non-GAAP measures to the most comparable GAAP
measures is set forth in tabular form following the Condensed Consolidated
Balance Sheets and Condensed Consolidated Statements of Operations.
                                                                                
  Forward-Looking Statements                                                    
                                                                                
This press release contains forward-looking statements. In some cases, you can
identify these statements by forward-looking words such as “aim,” “anticipate,”
“believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,”
“plan,” “potential,” “predict,” “should,” “would,” or “will,” the negative of
these terms, and other comparable terminology. These forward-looking statements,
which are subject to risks, uncertainties, and assumptions about us, may include
statements related to the potential benefits, uses and impacts of the Galleri
test, comparability of clinical study results to a real world setting, benefits
of population screening with existing or future versions of Galleri, commercial
and expansion plans, growth trends and reimbursement, potential regulatory
decision timeline and outcome, and impacts of our commercial strategies, among
others.
                                       4                                        
These statements are only predictions based on our current expectations and
projections about future events and trends. There are important factors that
could cause our actual results, level of activity, performance, or achievements
to differ materially and adversely from those expressed or implied by the
forward-looking statements, including those factors and numerous associated
risks discussed under the sections entitled “Risk Factors” in our Annual Report
on Form 10-K for the year ended December 31, 2025 and our subsequent Quarterly
Reports on Form 10-Q. Moreover, we operate in a dynamic and rapidly changing
environment. New risks emerge from time to time. It is not possible for our
management to predict all risks, nor can we assess the impact of all factors on
our business or the extent to which any factor, or combination of factors, may
cause actual results, level of activity, performance, or achievements to differ
materially and adversely from those contained in any forward-looking statements
we may make.

Forward-looking statements relate to the future and, accordingly, are subject to
inherent uncertainties, risks, and changes in circumstances that are difficult
to predict and many of which are outside of our control. Although we believe the
expectations and projections expressed or implied by the forward-looking
statements are reasonable, we cannot guarantee future results, level of
activity, performance, or achievements. Our actual results, financial condition
and success in our business strategies and operations may differ materially from
those indicated in the forward-looking statements. Except to the extent required
by law, we undertake no obligation to update any of these forward-looking
statements after the date of this press release to conform our prior statements
to actual results or revised expectations or to reflect new information or the
occurrence of unanticipated events.
                                                                                
  GRAIL Contacts                                                                
                                                                                
Corporate Communications

Kristen Davis

Trish Rowland

[email protected]

Investor Relations

Alex Dobbin

Alexis Tosti

[email protected]
                                       5                                        
                                                                                
                                  GRAIL, Inc.                                   
                                                                                
                                                                                
                     Condensed Consolidated Balance Sheets                      
                                                                                
                                  (unaudited)                                   
                                                                                
            (amounts in thousands, except share and per share data)             
                                                                                
                                              September 30,       December 31,  
                                                       2026               2025  
 ────────────────────────────────────────────────────────────────────────────── 
  Assets                                                                        
  Current assets:                                                               
  Cash and cash equivalents                $         28,976    $       249,727  
  Short-term marketable securities                  759,700            654,703  
  Accounts receivable, net                           18,998             18,295  
  Supplies                                           18,475             16,017  
  Prepaid expenses and other current                 16,649             15,107  
  assets                                                                        
  Total current assets                              842,798            953,849  
  Property and equipment, net                        42,691             51,813  
  Operating lease right-of-use assets                84,073             52,070  
  Restricted cash                                     6,943              6,974  
  Intangible assets, net                          1,746,806          1,850,556  
  Other non-current assets                            7,251              6,753  
  Total assets                             $      2,730,562    $     2,922,015  
  Liabilities and stockholders’ equity                                          
  Current liabilities:                                                          
  Accounts payable                         $         10,209    $         2,083  
  Accrued liabilities                                76,305             63,945  
  Operating lease liabilities, current                6,272             11,715  
  portion                                                                       
  Other current liabilities                           1,546              1,927  
  Total current liabilities                          94,332             79,670  
  Operating lease liabilities, net of                79,576             43,148  
  current portion                                                               
  Deferred tax liability, net                        99,742            218,583  
  Other non-current liabilities                       3,393              2,752  
  Total liabilities                                 277,043            344,153  
  Preferred stock, par value of $0.001                                          
  per                                                                           
  share; 50,000,000 shares authorized,                                          
  no                                                      —                  —  
  shares issued and outstanding as of                                           
  September 30, 2026 and December 31,                                           
  2025                                                                          
  Common stock $0.001 par value per                                             
  share,                                                                        
  1,500,000,000 shares authorized as of                                         
  September 30, 2026 and December 31,                                           
  2025                                                   45                 40  
  and 44,753,179 and 40,331,360 shares                                          
  issued and outstanding as of                                                  
  September                                                                     
  30, 2026 and December 31, 2025                                                
  Additional paid-in capital                     12,970,363         12,786,848  
  Accumulated other comprehensive                     1,794              2,655  
  income                                                                        
  Accumulated deficit                           -10,518,683        -10,211,681  
  Total stockholders' equity                      2,453,519          2,577,862  
  Total liabilities and stockholders'      $      2,730,562    $     2,922,015  
  equity                                                                        
                                                                                
                                       6                                        
                                                                                
                                  GRAIL, Inc.                                   
                                                                                
                                                                                
                Condensed Consolidated Statements of Operations                 
                                                                                
                                  (unaudited)                                   
                                                                                
            (amounts in thousands, except share and per share data)             
                                                                                
            Three    Septem…       Septem…    Nine      Septem…       Septemb…  
            Months       30,           30,    Months        30,            30,  
            Ended       2026          2025    Ended        2026           2025  
 ────────────────────────────────────────────────────────────────────────────── 
  Reven…                                                                        
  Scree…    $         37,269    $   32,807    $         119,743    $    96,319  
  reven…                                                                        
  Devel…                                                                        
  servi…                 266         3,387                3,264          7,256  
  reven…                                                                        
  Total               37,535        36,194              123,007        103,575  
  reven…                                                                        
  Costs                                                                         
  and                                                                           
  opera…                                                                        
  expen…                                                                        
  Cost                                                                          
  of                                                                            
  scree…                                                                        
  reven…                                                                        
  (excl…              22,032        15,910               66,623         52,379  
  of                                                                            
  amort…                                                                        
  of                                                                            
  intan…                                                                        
  asset…                                                                        
  Cost                                                                          
  of                                                                            
  devel…                 141           544                  951          2,216  
  servi…                                                                        
  reven…                                                                        
  Cost                                                                          
  of                                                                            
  reven…                                                                        
  —                   33,473        33,473              100,417        100,417  
  amort…                                                                        
  of                                                                            
  intan…                                                                        
  assets                                                                        
  Resea…                                                                        
  and                 44,073        48,647              139,523        148,898  
  devel…                                                                        
  Sales                                                                         
  and                 41,695        25,503              110,020         89,021  
  marke…                                                                        
  Gener…                                                                        
  and                 40,740        37,408              134,217        120,396  
  admin…                                                                        
  Intan…                                                                        
  and                                                                           
  other                    —             —               25,423         28,000  
  assets                                                                        
  impai…                                                                        
  Total                                                                         
  costs                                                                         
  and                182,154       161,485              577,174        541,327  
  opera…                                                                        
  expen…                                                                        
  Loss                                                                          
  from               -144,6…       -125,2…              -454,1…       -437,752  
  opera…                                                                        
  Other                                                                         
  incom…                                                                        
  Inter…               7,843         6,107               23,059         20,695  
  income                                                                        
  Other                                                                         
  income                -545           466                 -444           -929  
  (expe…                                                                        
  net                                                                           
  Total                                                                         
  other                7,298         6,573               22,615         19,766  
  incom…                                                                        
  net                                                                           
  Loss                                                                          
  before             -137,3…       -118,7…              -431,5…       -417,986  
  income                                                                        
  taxes                                                                         
  Benef…                                                                        
  from                33,753        29,741              124,550        108,811  
  income                                                                        
  taxes                                                                         
  Net       $        -103,5…    $  -88,977    $         -307,0…    $  -309,175  
  loss                                                                          
  Net                                                                           
  loss                                                                          
  per                                                                           
  share     $          -2.21    $    -2.46    $           -6.84    $     -8.73  
  —                                                                             
  Basic                                                                         
  and                                                                           
  Dilut…                                                                        
  Weigh…                                                                        
  shares                                                                        
  of                                                                            
  common                                                                        
  stock                                                                         
  used               46,777…       36,124…              44,858…       35,415,…  
  in                                                                            
  compu…                                                                        
  net                                                                           
  loss                                                                          
  per                                                                           
  share:                                                                        
                                                                                
                                       7                                        
                                                                                
                                  GRAIL, Inc.                                   
                                                                                
                                                                                
             Reconciliation of GAAP to Non-GAAP Financial Measures              
                                                                                
                                  (unaudited)                                   
                                                                                
                             (amounts in thousands)                             
                                                                                
          Three                               Nine                              
          Mont…                               Mont…                             
          Ended                               Ended                             
          Sept…             Sept…             Sept…             Sept…           
          30,               30,               30,               30,             
          2026              2025              2026              2025            
 ────────────────────────────────────────────────────────────────────────────── 
  Gro…    $        -18,…    $        -13,…    $        -44,…    $        -51,…  
  los…                                                                          
  Amo…                                                                          
  of               33,4…             33,4…             100,…             100,…  
  int…                                                                          
  ass…                                                                          
  Sto…               552               271             1,734             1,450  
  com…                                                                          
  Adj…                                                                          
  Gro…    $        15,9…    $        20,0…    $        57,1…    $        50,4…  
  Pro…                                                                          
  Adj…                                                                          
  Gro…               42%               55%               46%               49%  
  Mar…                                                                          
                                                                                
(1) Gross loss is calculated as total revenue less cost of screening revenue
(exclusive of amortization of intangible assets), cost of development services
revenue and cost of revenue—amortization of intangible assets.

(2) Adjusted Gross Margin is calculated as adjusted gross profit divided by
total revenue.
                                       8                                        
                                                                                
                                  GRAIL, Inc.                                   
                                                                                
                                                                                
             Reconciliation of GAAP to Non-GAAP Financial Measures              
                                                                                
                                  (unaudited)                                   
                                                                                
                             (amounts in thousands)                             
                                                                                
            Three    Septem…       Septem…    Nine      Septem…       Septemb…  
            Months       30,           30,    Months        30,            30,  
            Ended       2026          2025    Ended        2026           2025  
 ────────────────────────────────────────────────────────────────────────────── 
  Net       $        -103,5…    $  -88,977    $         -307,0…    $  -309,175  
  loss                                                                          
  Adjus…                                                                        
  to                                                                            
  exclu…                                                                        
  the                                                                           
  follo…                                                                        
  Amort…                                                                        
  of                  34,583        34,583              103,750        103,750  
  intan…                                                                        
  asset…                                                                        
  Stock…              14,109        14,139               50,459         44,518  
  compe…                                                                        
  Intan…                                                                        
  and                                                                           
  other                    —             —               25,423         28,000  
  assets                                                                        
  impai…                                                                        
  Depre…               3,892         4,399               12,207         13,686  
  Benef…                                                                        
  from               -33,753       -29,741              -124,5…       -108,811  
  income                                                                        
  taxes                                                                         
  Inter…              -7,843        -6,107              -23,059        -20,695  
  income                                                                        
  Restr…                   —             —                    —            -34  
  Adjus…    $        -92,580    $  -71,704    $         -262,7…    $  -248,761  
  EBITDA                                                                        
                                                                                
(1) Represents amortization of intangible assets, including developed technology
and trade names.

(2) Represents the impairment charge related to the deferred asset recognized in
connection with the Samsung SPA in the second quarter of 2026 and the in-process
research and development ("IPR&D") impairment charge in the prior period.
                                       9                                        

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/GRAL/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.